Treace Medical Concepts (NASDAQ:TMCI) Posts Quarterly Earnings Results

Treace Medical Concepts (NASDAQ:TMCI) posted its quarterly earnings results on Friday. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.06, FiscalAI reports. The firm had revenue of $45.38 million for the quarter, compared to the consensus estimate of $44.02 million. Treace Medical Concepts had a negative net margin of 29.44% and a negative return on equity of 67.04%.

Here are the key takeaways from Treace Medical Concepts’ conference call:

• Case volume growth accelerated to high single digits year over year in Q2, supported by market-share gains and broader adoption of Treace’s new bunion systems. Approximately 40% of Lapiplasty surgeons have now used at least one of the three systems launched in 2025.
• Treace raised its 2026 revenue guidance to $204 million-$212 million, up from a prior range of $202 million-$212 million, and expects revenue to return to positive growth in the seasonally strong fourth quarter.
• Profitability and cash trends improved, with Q2 adjusted EBITDA loss narrowing slightly to $3.5 million, operating expenses falling 8%, and year-to-date cash usage declining 57%. Full-year adjusted EBITDA guidance was improved to a loss of $3 million-$5 million.
• The company is expanding beyond bunion procedures through SuperBite, HyperPlate XM, GreatReleaseXM, and planned CartiBlaster launches, which management estimates could expand its U.S. addressable market by approximately $300 million.
• Q2 revenue fell 4% to $45.4 million, pressured by lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products. Management expects the associated average selling price headwind to persist through Q3.

Treace Medical Concepts Stock Performance

Shares of TMCI stock opened at $4.76 on Friday. The company has a market capitalization of $308.78 million, a P/E ratio of -4.91 and a beta of 1.37. Treace Medical Concepts has a fifty-two week low of $1.17 and a fifty-two week high of $7.78. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.53 and a current ratio of 3.58. The stock has a 50 day moving average price of $4.18 and a two-hundred day moving average price of $2.75.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wall Street Zen raised shares of Treace Medical Concepts from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings raised shares of Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Finally, Truist Financial upped their price target on shares of Treace Medical Concepts from $2.00 to $4.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $4.97.

Insider Activity

In other news, CEO John T. Treace bought 61,750 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The shares were bought at an average cost of $2.62 per share, with a total value of $161,785.00. Following the completion of the purchase, the chief executive officer directly owned 7,158,313 shares in the company, valued at $18,754,780.06. This represents a 0.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders have purchased a total of 371,600 shares of company stock valued at $1,104,801 in the last quarter. 23.42% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Treace Medical Concepts

A number of large investors have recently added to or reduced their stakes in TMCI. Osaic Holdings Inc. raised its stake in shares of Treace Medical Concepts by 328.3% during the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock valued at $28,000 after acquiring an additional 3,674 shares during the last quarter. Captrust Financial Advisors bought a new stake in shares of Treace Medical Concepts in the second quarter worth about $62,000. Graham Capital Management L.P. bought a new position in Treace Medical Concepts during the 4th quarter valued at approximately $27,000. Mercer Global Advisors Inc. ADV bought a new position in Treace Medical Concepts during the 3rd quarter valued at approximately $87,000. Finally, HighTower Advisors LLC purchased a new stake in Treace Medical Concepts in the 4th quarter worth approximately $33,000. Institutional investors own 84.08% of the company’s stock.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.